Halozyme Therapeutics, Inc. (HALO)
HALONASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)
$103.67
+0.7450 (+0.72%) today
Regular session, Nov 10, 12:47 PM ET
- Market cap
- $11.82bn
- P/E
- 18.6
- EPS, last 4 quarters
- $5.57
- Dividend yield
- –
- Day range
- $101.38 to $105.45
- 52-week range
- $61.23 to $134.00
- Average volume
- 2.32m
- Previous close
- $102.92
Analysts
7 coveringBuy4 buy, 3 hold, 0 sell
Targets a year out average $119.17, +15.0% from here
Earnings
next estimate $2.51Next report
Dec 2025
-116.9%
Mar 2026
+1.4%
Jun 2026
+25.4%
Sep 2026
+4.6%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $451.77m | $376.71m | $481.00m | $492.97m |
| Gross profit | $373.00m | $297.47m | $401.83m | $410.50m |
| Operating income | -$92.89m | $184.52m | $287.65m | $294.97m |
| Net income | -$141.59m | $150.05m | $229.91m | $247.05m |
Last four quarters: revenue $1.80bn, margin 26.9%, free cash flow $885.88m
News
8 latest- IBRX Q3 Earnings Miss, Anktiva Sales Decline Q/Q, Stock Down 18%Zacks · 3 hours ago
- Are Medical Stocks Lagging Halozyme Therapeutics (HALO) This Year?Zacks · 4 hours ago
- 3 Reasons Argenx Could Be a Top Biotech Stock for the Next DecadeThe Motley Fool · 1 day ago
- Halozyme Stock Down Despite Q3 Earnings and Revenue BeatZacks · 4 days ago
- J&J's RYBREVANT FASPRO Approved By FDA For Advanced Head And Neck Cancer; Stock Down RTTNews · 4 days ago
- HALO Q3 Earnings Call Highlights Royalty Growth and Patent DisputeZacks · 4 days ago
- Halozyme (HALO) Q3 2026 Earnings Call TranscriptThe Motley Fool · 4 days ago
- What Halozyme Therapeutics (HALO) Said on Its Q3 Earnings CallMarketBeat · 5 days ago
The company
Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of reducing treatment burden and improving convenience. ENHANZE has touched more than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen Pharmaceuticals, Merus N.V., GSK, and Incyte. Halozyme expanded its drug delivery technology portfolio to develop partner products using Hypercon and Surf Bio's hyperconcentration technology, recently renamed as Aerocon.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- halozyme.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.